Neutrolis, Inc. is a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cell in our body. Neutrolis’ lead program targets Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the innate immune system and play an important role in chronic and acute diseases. Based in Cambridge, MA, Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and supported by seasoned business leaders.
Location: United States, Massachusetts, Cambridge
Employees: 1-10
Total raised: $23.1M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | EGI Capita... | egicapital... |
| - | Prefix Cap... | prefixcapi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.12.2021 | Series A | $23.1M | - |